Article
LRH-1/NR5A2 targets mitochondrial dynamics to reprogram type 1 diabetes macrophages and dendritic cells into an immune tolerance phenotype.
Clinical and translational medicine - 1 Dec 2024
Cobo-Vuilleumier Nadia, Rodríguez-Fernandez Silvia, López-Noriega Livia, Lorenzo Petra I, Franco Jaime M, Lachaud Christian C, Vazquez Eugenia Martin, Legido Raquel Araujo, Dorronsoro Akaitz, López-Férnandez-Sobrino Raul, Fernández-Santos Beatriz, Serrano Carmen Espejo, Salas-Lloret Daniel, van Overbeek Nila, Ramos-Rodriguez Mireia, Mateo-Rodríguez Carmen, Hidalgo Lucia, Marin-Canas Sandra, Nano Rita, Arroba Ana I, Caro Antonio Campos, Vertegaal Alfred Co, Martin-Montalvo Alejandro, Martín Franz, Aguilar-Diosdado Manuel, Piemonti Lorenzo, Pasquali Lorenzo, Prieto Roman González, Sánchez Maria Isabel García, Eizirik Decio L, Martínez-Brocca Maria Asuncion, Vives-Pi Marta, Gauthier Benoit R
Abstract excerpt
BACKGROUND: The complex aetiology of type 1 diabetes (T1D), characterised by a detrimental cross-talk between the immune system and insulin-producing beta cells, has hindered the development of effective disease-modifying therapies. The discovery that the pharmacological activation of LRH-1/NR5A2 can reverse hyperglycaemia in mouse models of T1D by attenuating the autoimmune attack coupled to beta cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
